Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:infliximab
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AB02
|
| gptkbp:biosimilar |
gptkb:infliximab
|
| gptkbp:brand |
gptkb:Renflexis
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| https://www.w3.org/2000/01/rdf-schema#label |
infliximab-abda
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis ulcerative colitis rheumatoid arthritis ankylosing spondylitis plaque psoriasis |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Samsung_Bioepis
|
| gptkbp:marketedAs |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
TNF-alpha inhibitor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:bfsParent |
gptkb:Ixifi
gptkb:Renflexis |
| gptkbp:bfsLayer |
6
|